Cefpimizole
Cefpimizole Basic information
- Product Name:
- Cefpimizole
- Synonyms:
-
- Pyridinium, 1-[[(6R,7R)-2-carboxy-7-[[(2R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt
- Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt, [6R-[6α,7β(R*)]]-
- U 63196
- (6R,7R)-7-[[(2R)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfonatoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- CEFPIMIZOLE
- 1-[[(6R)-2-Carboxylato-7α-[[(R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium
- Cefpimizol
- cefpimizole:(6r,7r)-7-(((2r)-2-((5-carboxy-1h-IMIDAZOLE-4-carbonyl)amino)-2-phenylacetyl)amino)-8-oxo-3-((4-(2-sulfonatoethyl)pyridin-1-ium-1-yl)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxyli
- CAS:
- 84880-03-5
- MF:
- C28H26N6O10S2
- MW:
- 670.67
- Mol File:
- 84880-03-5.mol
Cefpimizole Usage And Synthesis
Description
Cefpimizole sodium is a third-generation cephalosporin with a spectrum of activity somewhat narrower than cefotaxime and cefoperazone.
Originator
Ajinomoto (Japan)
Uses
Antibacterial.
Definition
ChEBI: Cefpimizole is a peptide.
brand name
Ajicef; Renilan
Antimicrobial activity
A semisynthetic parenteral cephalosporin. It exhibits modest
activity compared to other antipseudomonal cephalosporins.
Like cefoperazone, it is susceptible to many enterobacterial
β-lactamases. In volunteers receiving 0.1–1 g intramuscularly,
mean peak plasma concentrations reached 15–20 and
35–40 mg/L, respectively. There was no accumulation when
the dose was repeated every 8 h for 7 days. No metabolites
have been detected. The plasma elimination half-life is 1.8–
2.1 h. The principal route of elimination is renal, 70–80%
being recovered unchanged in the urine.
Significant pain at the site of infection has been a prominent
adverse event. It is no longer widely available.
Cefpimizole Preparation Products And Raw materials
Raw materials
CefpimizoleSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Tel
- +86-029-89586680 +86-18192503167
- 1026@dideu.com
- Tel
- +8618523575427
- sales@conier.com